“Conceptual” is doing a lot of work in this story.
Butterfly Network’s investor relations infrastructure confirms the company as a publicly traded SEC-reporting entity, the kind of organization that discloses material contracts in 8-K filings. A co-development agreement with Midjourney Medical, if structured as The Wire reports, would be a disclosable event. The IR page resolves; the specific filing text confirming the $74M figure and 5-year term wasn’t captured in the fetched content. Treat the $74M figure as reported but not yet confirmed against the actual filing. BFLY shares reportedly surged significantly on the announcement. A precise figure for the stock move requires a sourced close price, not a range.
What’s confirmed, independently: Midjourney Medical launched a medical subsidiary and unveiled a conceptual ultrasound scanner designed to perform whole-body scans in 60 seconds. That characterization, “conceptual”, comes from Digg’s reporting, which is the only independent source whose content was actually fetched for this story. Midjourney’s own materials may use different language. The editorial distinction matters.
Disputed Claim
The technology, as described, combines water-immersion ultrasound tomography with an array of approximately 40 Butterfly Network chips. The 60-second whole-body claim, if accurate, would represent a meaningful advance over conventional point-of-care ultrasound, which requires multiple transducer positions and significant operator time. The “MRI-comparable” characterization is a vendor claim without clinical validation. No peer-reviewed imaging study confirms the diagnostic equivalence. Eval status is correctly marked pending.
No FDA clearance exists for this device. That’s not a minor technical detail, it’s the central regulatory fact. Medical imaging devices in the US require FDA clearance before clinical use. The pathway for an “ultrasonic CT” device performing diagnostic full-body imaging would be a 510(k) or PMA, depending on how it’s classified. Midjourney Medical’s announced deployment plan targets “Bay Area wellness spas by 2027,” not hospital radiology departments. The wellness framing isn’t incidental, it’s the regulatory strategy. Wellness and spa applications face different regulatory requirements than clinical diagnostic devices. Whether that framing holds as the product develops is the question radiologists and regulators will be watching.
The catch is the gap between “conceptual scanner unveiled at a launch event” and “deployed medical hardware.” Butterfly Network’s chipsets are real production technology, the company has shipped ultrasound chips embedded in handheld clinical devices. A co-development agreement between Butterfly and a well-funded generative AI company is a credible premise. The 60-second full-body scan at MRI-comparable diagnostic quality is the part that requires clinical validation that hasn’t happened yet.
What to Watch
Don’t lead with the stock move until you have a confirmed figure. Don’t characterize this as a cleared medical device. Do watch the Butterfly Network 8-K filings in the next 30 days for confirmation of the contract terms, if the deal is SEC-disclosable as reported, the filing will contain the specific language.
The deeper story here isn’t the scanner. A generative image company has pivoted to medical hardware, structured a multimillion-dollar chip supply agreement, and announced consumer deployment through a wellness channel that avoids the FDA’s clinical device pathway. That’s a strategic pattern worth tracking across the generative AI sector, not just a product announcement.